cyclophosphamide + pegylated liposomal doxorubicin + cisplatin

This is a **combination chemotherapy regimen** consisting of three cytotoxic agents: **cyclophosphamide** (an alkylating agent), **pegylated liposomal doxorubicin** (an anthracycline topoisomerase II inhibitor formulated in PEGylated liposomes), and **cisplatin** (a platinum-based DNA crosslinker). Each drug contributes different antineoplastic mechanisms, resulting in broad-spectrum cytotoxic activity. - **Cyclophosphamide** is metabolized to active compounds that alkylate DNA leading to crosslinking and inhibition of DNA replication and cell death, with activity against various solid and hematologic malignancies. - **Pegylated liposomal doxorubicin** delivers doxorubicin in liposomes with pegylation, reducing cardiotoxicity and improving pharmacokinetics; it intercalates into DNA and inhibits topoisomerase II, blocking DNA synthesis and repair. - **Cisplatin** forms inter- and intra-strand DNA crosslinks, disrupting DNA structure and triggering apoptosis. This combination—though not a standardized named regimen—is used or has been studied in solid tumors such as **metastatic breast cancer, ovarian cancer, sarcoma, and pleural mesothelioma**, offering a multidrug approach targeting tumor cells via complementary mechanisms[1][2][3][6].